PATENT CLAIM ANALYSIS

Application Number: 15759723
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "085200"]

Abstract:
This disclosure describes an adaptive NK cell, an isolated population of adaptive Natural Killer (NK) cells, a composition including an adaptive NK cell, and methods for producing, preparing, and using an adaptive NK cell or an isolated population or composition including an adaptive NK cell. The adaptive NK cells may be used to treat a viral infection or a tumor.

Claim (Index 51):
The method of  claim 50 , wherein\n (i) the TIGIT inhibitor comprises an antibody against TIGIT; (ii) the adaptive NK cell is at least one of CD57 + , SYK \u2212 , Fc\u03b5R\u03b3 \u2212 , EAT-2 \u2212 , CD45RO + , and CD45RA \u2212 ; (iii) the adaptive NK cell exhibits reduced expression of PLZF compared to the population of NK cells prior to culture; (iv) the adaptive NK cell exhibits an enhanced anti-tumor immune activity compared to the population of NK cells prior to culture; or (v) the adaptive NK cell exhibits one or more of increased cytotoxicity, increased cytokine production, increased persistence, and increased resistance to T regulatory cells compared to the population of NK cells prior to culture.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.91667
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12855203', '13865762', '13946266', '14547084', '15167166']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6985538274580549
- 35 USC 102 Novelty (BERT): 0.5372972283281531
- Combined Prediction Score: 0.6824281675450647
- Mean Citation Score: 332.60156
- Max Citation Score: 374.96857
- Similarity Product: 265.47019491366564

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test